DUBLIN--(BUSINESS WIRE)--The "Osteoporosis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Osteoporosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 5, 5, 13, 1, 55 and 13 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 11 and 14 molecules, respectively.
Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Osteoporosis - Overview
- Osteoporosis - Therapeutics Development
- Osteoporosis - Therapeutics Assessment
- Osteoporosis - Companies Involved in Therapeutics Development
- Osteoporosis - Drug Profiles
- Osteoporosis - Dormant Projects
- Osteoporosis - Discontinued Products
- Osteoporosis - Product Development Milestones
-
Appendix
Companies Mentioned
- Abreos Biosciences Inc
- Alize Pharma SAS
- Alvogen Korea Co Ltd
- Bristol-Myers Squibb Co
- Cadila Healthcare Ltd
- Cellmid Ltd
- ChoDang Pharm Co Ltd
- Chugai Pharmaceutical Co Ltd
- Corium International Inc
- Critical Pharmaceuticals Ltd
- Daiichi Sankyo Co Ltd
- ElexoPharm GmbH
- EndoCeutics Inc
- Hanmi Pharmaceuticals Co Ltd
- Haoma Medica Ltd
- Immunovo BV
- Immunwork Inc
- Intas Pharmaceuticals Ltd
- Ipsen SA
- Lupin Ltd
- Luye Pharma Group Ltd
- mAbxience SA
- Merck & Co Inc
- Mereo Biopharma Group Plc
- NIBEC
- Omeros Corp
- Oncobiologics Inc
- Paras Biopharmaceuticals Finland Oy
- Pfenex Inc
- PhytoHealth Corp
- R Pharm
- Viking Therapeutics Inc
- Wroclawskie Centrum Badan EIT+ Sp z oo
- Yooyoung Pharm Co Ltd
For more information about this report visit https://www.researchandmarkets.com/research/mvf356/osteoporosis?w=4
